ITGA2B and eosinophilic esophagitis: Although the response rate of 44% (11 of 25 subjects) in our study is comparable to the experience of others treating EoE [32], we do not know whether eight weeks is optimal for determination of disease responsiveness and how percent CD41+ eosinophils, neutrophils, and monocytes, and the myeloid PCA factor change during the treatment period.